% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Zaimenko:143600,
author = {I. Zaimenko and C. Jaeger and H. Brenner$^*$ and J.
Chang-Claude$^*$ and M. Hoffmeister$^*$ and C.
Grötzinger$^*$ and K. Detjen and S. Burock and C. A.
Schmitt$^*$ and U. Stein$^*$ and J. Lisec},
title = {{N}on-invasive metastasis prognosis from plasma metabolites
in stage {II} colorectal cancer patients: {T}he {DACHS}
study.},
journal = {International journal of cancer},
volume = {145},
number = {1},
issn = {1097-0215},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2019-01180},
pages = {221 - 231},
year = {2019},
abstract = {Metastasis is the main cause of death from colorectal
cancer (CRC). About $20\%$ of stage II CRC patients develop
metastasis during the course of disease. We performed
metabolic profiling of plasma samples from non-metastasized
and metachronously metastasized stage II CRC patients to
assess the potential of plasma metabolites to serve as
biomarkers for stratification of stage II CRC patients
according to metastasis risk. We compared the metabolic
profiles of plasma samples prospectively obtained prior to
metastasis formation from non-metastasized vs.
metachronously metastasized stage II CRC patients of the
German population-based case-control multicenter DACHS study
retrospectively. Plasma samples were analyzed from stage II
CRC patients for whom follow-up data including the
information on metachronous metastasis were available. To
identify metabolites distinguishing non-metastasized from
metachronously metastasized stage II CRC patients robust
supervised classifications using decision trees and support
vector machines were performed and verified by 10-fold
cross-validation, by nested cross-validation and by
traditional validation using training and test sets. We
found that metabolic profiles distinguish non-metastasized
from metachronously metastasized stage II CRC patients.
Classification models from decision trees and support vector
machines with 10-fold cross-validation gave average accuracy
of 0.75 (sensitivity 0.79, specificity 0.7) and 0.82
(sensitivity 0.85, specificity 0.77), respectively,
correctly predicting metachronous metastasis in stage II CRC
patients. Taken together, plasma metabolic profiles
distinguished non-metastasized and metachronously
metastasized stage II CRC patients. The classification
models consisting of few metabolites stratify non-invasively
stage II CRC patients according to their risk for
metachronous metastasis.},
cin = {C070 / C020 / L201 / L101},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C020-20160331 /
I:(DE-He78)L201-20160331 / I:(DE-He78)L101-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30560999},
doi = {10.1002/ijc.32076},
url = {https://inrepo02.dkfz.de/record/143600},
}